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Background: Cangrelor is a parenteral P2Y12 receptor antagonist with rapid and potent platelet inhibitory effects. Limited information is available 
on the pharmacodynamic (PD) effects of this agent on platelet signaling pathways. The aim of this study was to assess the PD effects of cangrelor in 
an in vitro model.
Methods: Aspirin-treated patients (n=30) with stable coronary artery disease were studied. In vitro incubation with 4 escalating concentrations 
of cangrelor (5nM, 50nM, 500nM, 5000nM) was used for PD determinations which included: the P2Y12 reactivity index (PRI) as assessed by 
flow cytometric assessment of VASP-P and multiple electrode platelet aggregometry (MEA) following stimuli with arachidonic acid (AA), adenosine 
diphosphate (ADP), collagen and thrombin receptor agonist peptide (TRAP).
Results: A significant reduction in P2Y12 receptor signaling as measured by PRI values was observed with an increase in cangrelor concentrations 
(Table). In addition, cangrelor was also associated with dose-dependent effects on PD measures reflecting other pivotal platelet signaling pathways 
as measured by multiple agonists using MEA (Table).
Pharmacodinamic assessments with and without in vitro cangrelor
Baseline 5μM 50μM 500μM 5000μM P for trend
PRI (%) 86.7±4.4 77.5±8.8 47.1±15.3 17.4±11.6 7.0±7.2 <0.001
AA (AU*min) 275±226 166±154 120±132 111±130 89±83 <0.001
ADP (AU*min) 551±208 253±97 157±48 130±58 121±54 <0.001
Collagen (AU*min) 378±129 284±124 246±122 241±99 221±91 <0.001
TRAP (AU*min) 824±221 659±247 548±241 481±216 469±194 <0.001
Conclusion: This in vitro PD investigation shows that escalating concentrations of cangrelor is associated with incremental inhibitory effects not 
only of P2Y12 receptor signaling, but also of other pivotal platelet signaling pathways. These findings support the pivotal role mediated by the P2Y12 
receptor on multiple platelet signaling processes.
